NCT05582096

A Study of LY3457263 in Obese Participants

A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	LY3457263	Administered SC.
DRUG	Tirzepatide	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2022-11-11
• Primary completion: 2023-06-08
• Completion: 2023-06-08
• First posted: 2022-10-17
• Last updated: 2023-07-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study